| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DBVT | Exit | DBV TECHNOLOGIES S Asponsored adr | $0 | – | -18,265 | -100.0% | -0.02% | – |
| Exit | ZURA BIO LTD | $0 | – | -9,917 | -100.0% | -0.04% | – | |
| PASG | Exit | PASSAGE BIO INC | $0 | – | -190,124 | -100.0% | -0.08% | – |
| NKTR | Exit | NEKTAR THERAPEUTICS | $0 | – | -1,766,815 | -100.0% | -0.70% | – |
| Exit | THESEUS PHARMACEUTICALS INC | $0 | – | -702,415 | -100.0% | -1.25% | – | |
| CCCC | Exit | C4 THERAPEUTICS INC | $0 | – | -1,019,230 | -100.0% | -1.25% | – |
| Exit | BIONOMICS LIMITEDads | $0 | – | -815,512 | -100.0% | -1.46% | – | |
| SLN | Exit | SILENCE THERAPEUTICS PLCads | $0 | – | -235,787 | -100.0% | -1.53% | – |
| KNTE | Exit | KINNATE BIOPHARMA INC | $0 | – | -1,997,006 | -100.0% | -1.85% | – |
| PIRS | Exit | PIERIS PHARMACEUTICALS INC | $0 | – | -9,775,849 | -100.0% | -1.93% | – |
| AUTL | Exit | AUTOLUS THERAPEUTICS PLCspon ads | $0 | – | -1,363,025 | -100.0% | -2.10% | – |
| STOK | Exit | STOKE THERAPEUTICS INC | $0 | – | -1,710,154 | -100.0% | -4.46% | – |
| GHRS | Exit | GH RESEARCH PLCordinary shares | $0 | – | -1,103,178 | -100.0% | -7.33% | – |
| Exit | TSCAN THERAPEUTICS INC | $0 | – | -5,224,600 | -100.0% | -8.85% | – | |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -994,161 | -100.0% | -9.80% | – |
| MRUS | Exit | MERUS N V | $0 | – | -1,150,225 | -100.0% | -17.94% | – |
| ALPN | Exit | ALPINE IMMUNE SCIENCES INC | $0 | – | -2,404,614 | -100.0% | -18.21% | – |
| CABA | Exit | CABALETTA BIO INC | $0 | – | -2,106,000 | -100.0% | -21.20% | – |
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MERUS N V | 8 | Q3 2023 | 21.9% |
| ALPINE IMMUNE SCIENCES INC | 8 | Q3 2023 | 20.2% |
| CYMABAY THERAPEUTICS INC | 8 | Q3 2023 | 10.0% |
| THESEUS PHARMACEUTICALS INC | 8 | Q3 2023 | 5.6% |
| PIERIS PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
| KINNATE BIOPHARMA INC | 7 | Q3 2023 | 18.0% |
| PARDES BIOSCIENCES INC | 7 | Q2 2023 | 11.0% |
| PASSAGE BIO INC | 7 | Q3 2023 | 4.0% |
| BELLUS HEALTH INC NEW | 6 | Q1 2023 | 22.7% |
| CABALETTA BIO INC | 4 | Q3 2023 | 22.6% |
View Lynx1 Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-05-30 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-04-23 |
| SC 13G | 2024-04-01 |
| SC 13G | 2024-03-29 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Lynx1 Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.